Stock News

EPS for Philip Morris International Inc. (PM) Expected At $1.25; Sangamo Therapeutics, Inc. (SGMO) Had 7 Bulls

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences had 27 analyst reports since August 8, 2015 according to SRatingsIntel. Wedbush maintained it with “Hold” rating and $6.0 target in Wednesday, November 15 report. On Wednesday, September 2 the stock rating was maintained by Jefferies with “Buy”. The stock has “Buy” rating by Cowen & Co on Friday, September 4. The company was initiated on Friday, December 4 by Wells Fargo. The company was downgraded on Thursday, August 4 by Janney Capital. The rating was downgraded by Zacks to “Sell” on Tuesday, September 8. Jefferies reinitiated Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Thursday, June 22 with “Buy” rating. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Buy” rating given on Friday, October 23 by Jefferies. The rating was maintained by Piper Jaffray on Thursday, August 10 with “Hold”. The rating was downgraded by PiperJaffray on Wednesday, October 19 to “Neutral”. See Sangamo Therapeutics, Inc. (NASDAQ:SGMO) latest ratings:

21/05/2018 Broker: Wedbush Rating: Hold New Target: $9.0000 Maintain
13/03/2018 Broker: Wedbush Rating: Hold New Target: $8.0 Maintain
22/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $32.0 Maintain
22/02/2018 Broker: Jefferies Rating: Buy New Target: $33.0 Maintain
22/02/2018 Broker: Wells Fargo Rating: Buy Maintain
03/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $25.0 Maintain

Analysts expect Philip Morris International Inc. (NYSE:PM) to report $1.25 EPS on July, 19.They anticipate $0.11 EPS change or 9.65% from last quarter’s $1.14 EPS. PM’s profit would be $1.94 billion giving it 16.17 P/E if the $1.25 EPS is correct. After having $1.00 EPS previously, Philip Morris International Inc.’s analysts see 25.00% EPS growth. The stock increased 1.01% or $0.81 during the last trading session, reaching $80.84. About 7.47M shares traded or 4.22% up from the average. Philip Morris International Inc. (NYSE:PM) has declined 32.76% since June 20, 2017 and is downtrending. It has underperformed by 45.33% the S&P500. Some Historical PM News: ; 21/03/2018 – Philip Morris Ceases All Cigarette Production At Greek Facility, To Make Only Smoke-free Products — MarketWatch; 29/03/2018 – PHILIP MORRIS INTERNATIONAL INC – IT IS PROPOSED THAT 14 NOMINEES FOR DIRECTOR ARE ELECTED AT ANNUAL MEETING, INCLUDING A NEW NOMINEE; 21/03/2018 – Philip Morris: Facility to Be Fully Operational by End of 2018; 18/05/2018 – Government proposal leaves markets gasping — and ltalians vaping; 19/04/2018 – PHILIP MORRIS INTERNATIONAL – 2018 FY DILUTED EPS FORECAST ASSUMES FULL-YEAR EFFECTIVE TAX RATE OF ABOUT 26%; 19/04/2018 – Buy Philip Morris Even as People Quit Smoking: Street Wrap; 19/04/2018 – PHILIP MORRIS INTERNATIONAL – 2018 FY FORECAST ASSUMES CURRENCY-NEUTRAL NET REVENUE GROWTH OF ABOUT 8.0%; 25/04/2018 – Coronation Fund Managers Adds Philip Morris, Exits Alibaba: 13F; 19/04/2018 – PHILIP MORRIS SEES 2018 CAPITAL EXPENDITURES OF ABOUT $1.7B; 19/04/2018 – PHILIP MORRIS INTERNATIONAL INC PM.N SEES FY 2018 SHR $5.25 TO $5.40

Investors sentiment decreased to 1.24 in 2018 Q1. Its down 0.16, from 1.4 in 2017Q4. It worsened, as 12 investors sold Sangamo Therapeutics, Inc. shares while 62 reduced holdings. 46 funds opened positions while 46 raised stakes. 53.36 million shares or 0.26% more from 53.22 million shares in 2017Q4 were reported. Utd Cap Fin Advisers Ltd Liability Com owns 32,314 shares for 0% of their portfolio. First Midwest Natl Bank Division invested in 15,879 shares or 0.04% of the stock. 555,635 are held by Wells Fargo & Mn. Tci Wealth Advsr Inc invested in 1,200 shares. The Manitoba – Canada-based Great West Life Assurance Can has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Davenport And Limited has 65,500 shares. Bluemountain Cap Ltd Liability Co reported 0.02% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Meeder Asset Management holds 0% or 1,429 shares in its portfolio. Dekabank Deutsche Girozentrale reported 38,200 shares or 0.01% of all its holdings. Mckinley Cap Mngmt Llc Delaware accumulated 0% or 3,432 shares. State Common Retirement Fund invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Aperio Grp Lc reported 11,644 shares stake. Stratos Wealth Prns has 2,909 shares. California Employees Retirement Systems invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). West Oak Llc has 50 shares.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.67 billion. The companyÂ’s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Since January 2, 2018, it had 0 insider purchases, and 19 insider sales for $2.88 million activity. Mento Steven J sold $219,546 worth of stock. Another trade for 8,163 shares valued at $163,260 was sold by Herberts Curt A. III. Shares for $87,065 were sold by Conner Edward R. on Friday, April 6. Yi Kathy had sold 5,000 shares worth $127,812 on Thursday, March 15. The insider Ramasastry Saira sold $235,080.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on June 20, 2018, also Seekingalpha.com with their article: “Sangamo Therapeutics: Investability Outlook” published on June 13, 2018, Streetinsider.com published: “UPDATE: BofA/Merrill Lynch Starts Sangamo BioSciences (SGMO) at Buy Citing Upcoming Catalysts” on June 20, 2018. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Seekingalpha.com and their article: “Crispr On Hold While Sangamo Accelerates” published on June 04, 2018 as well as Nasdaq.com‘s news article titled: “New Research Coverage Highlights Accenture, Chico’s FAS, The Allstate, Sangamo Therapeutics, ABB, and First …” with publication date: June 13, 2018.

The stock increased 3.13% or $0.5 during the last trading session, reaching $16.45. About 1.82M shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 100.00% since June 20, 2017 and is uptrending. It has outperformed by 87.43% the S&P500. Some Historical SGMO News: ; 24/04/2018 – SANGAMO THERAPEUTICS FILES MIXED SECURITIES SHELF; 24/04/2018 – Sangamo Therapeutics Announces Proposed Public Offering of Common Stk; 21/03/2018 – Glancy Prongay & Murray LLP Announces Investigation on Behalf of Sangamo Therapeutics, Inc. Investors (SGMO); 24/04/2018 – SANGAMO THERAPEUTICS – SEES USING NET PROCEEDS FROM OFFERING TO SUPPORT OWN, PARTNERED GENE THERAPY, GENOME EDITING, CELL THERAPY, AMONG OTHER THINGS; 16/05/2018 – BIOVERATIV, SANGAMO CITE GENE-EDITED CELL THERAPY BIVV003; 05/03/2018 Sangamo Therapeutics Announces Presentations At Upcoming Investor Conferences; 17/04/2018 – SANGAMO THERAPEUTICS SAYS ON APRIL 17, CO ANNOUNCED A DATA SECURITY INCIDENT INVOLVING COMPROMISE OF A SENIOR EXECUTIVE’S COMPANY EMAIL ACCOUNT; 16/05/2018 – Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell; 04/04/2018 – Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program; 03/05/2018 – Sangamo Therapeutics Announces Senior Leadership Changes

Since February 21, 2018, it had 4 insider purchases, and 3 insider sales for $6.75 million activity. Another trade for 13,650 shares valued at $1.43M was made by FIRESTONE MARC S on Wednesday, February 21. 6,000 shares valued at $489,360 were bought by Zielinski Miroslaw on Friday, April 27. Shares for $248,282 were bought by Whitson Jerry on Wednesday, April 25. On Friday, May 11 Li Jennifer bought $3.25 million worth of Philip Morris International Inc. (NYSE:PM) or 40,000 shares. The insider Geissler Werner bought 48,750 shares worth $3.97M. $8.21 million worth of Philip Morris International Inc. (NYSE:PM) was sold by CAMILLERI LOUIS C on Wednesday, May 9. 49,000 shares were sold by CALANTZOPOULOS ANDRE, worth $5.08 million on Wednesday, February 21.

Investors sentiment decreased to 0.91 in 2018 Q1. Its down 0.20, from 1.11 in 2017Q4. It dropped, as 61 investors sold Philip Morris International Inc. shares while 545 reduced holdings. 126 funds opened positions while 427 raised stakes. 1.09 billion shares or 0.05% less from 1.09 billion shares in 2017Q4 were reported. Lodestar Investment Counsel Ltd Il has 0.46% invested in Philip Morris International Inc. (NYSE:PM) for 39,763 shares. Wolverine Asset Mgmt reported 0% of its portfolio in Philip Morris International Inc. (NYSE:PM). Cubist Systematic Strategies Limited Liability Company owns 50,024 shares. Moreover, Two Sigma Securities Ltd Liability Corp has 0.02% invested in Philip Morris International Inc. (NYSE:PM) for 39,932 shares. Sterling Investment Inc owns 19,591 shares. Advsrs Asset Management accumulated 283,312 shares or 0.49% of the stock. Pure Financial Advisors Inc accumulated 3,965 shares. Moreover, Scotia Capital Incorporated has 0.02% invested in Philip Morris International Inc. (NYSE:PM) for 17,838 shares. Shufro Rose Com Ltd Limited Liability Company has 0.02% invested in Philip Morris International Inc. (NYSE:PM) for 2,400 shares. Connor Clark Lunn Inv Mngmt owns 535,307 shares. Lincoln Cap Ltd Co has invested 0.16% in Philip Morris International Inc. (NYSE:PM). Retail Bank Of Nova Scotia holds 0.13% in Philip Morris International Inc. (NYSE:PM) or 245,891 shares. Salem Inv Counselors holds 28,704 shares. Grassi Mngmt accumulated 66,259 shares. State Street has invested 0.47% in Philip Morris International Inc. (NYSE:PM).

Among 21 analysts covering Philip Morris International (NYSE:PM), 16 have Buy rating, 1 Sell and 4 Hold. Therefore 76% are positive. Philip Morris International had 63 analyst reports since August 24, 2015 according to SRatingsIntel. The stock of Philip Morris International Inc. (NYSE:PM) has “Buy” rating given on Friday, October 13 by Piper Jaffray. The firm has “Buy” rating by Cowen & Co given on Thursday, July 20. Societe Generale upgraded Philip Morris International Inc. (NYSE:PM) rating on Thursday, April 21. Societe Generale has “Hold” rating and $99 target. Bank of America downgraded the stock to “Neutral” rating in Wednesday, January 4 report. The company was maintained on Friday, May 18 by Stifel Nicolaus. The firm earned “Buy” rating on Tuesday, October 10 by Wells Fargo. The firm earned “Buy” rating on Friday, October 20 by Societe Generale. The stock of Philip Morris International Inc. (NYSE:PM) earned “Outperform” rating by BNP Paribas on Tuesday, March 8. The stock has “Neutral” rating by Citigroup on Friday, October 20. As per Wednesday, April 20, the company rating was maintained by Goldman Sachs.

More notable recent Philip Morris International Inc. (NYSE:PM) news were published by: Seekingalpha.com which released: “The Pain Of Philip Morris” on June 12, 2018, also Seekingalpha.com with their article: “Philip Morris: A Killer Stock” published on June 08, 2018, Seekingalpha.com published: “Philip Morris: Investors Are Ignoring This” on May 28, 2018. More interesting news about Philip Morris International Inc. (NYSE:PM) were released by: Seekingalpha.com and their article: “Philip Morris: No Buyback Now” published on June 04, 2018 as well as Fool.com‘s news article titled: “3 Reasons Philip Morris International Investors Should Be More Afraid Than Ever” with publication date: June 01, 2018.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *